Use of an attenuated leishmanial parasite as an immunoprophylactic and immunotherapeutic agent against murine visceral leishmaniasis
about
9- O-acetylated sialic acids enhance entry of virulent Leishmania donovani promastigotes into macrophages.Identification of novel Leishmania donovani antigens that help define correlates of vaccine-mediated protection in visceral leishmaniasisA perspective on the emergence of sialic acids as potent determinants affecting leishmania biology.Leishmania donovani Utilize Sialic Acids for Binding and Phagocytosis in the Macrophages through Selective Utilization of Siglecs and Impair the Innate Immune Arm.Evaluation of s.c. route of immunization by homologous radio attenuated live vaccine in experimental murine model of visceral leishmaniasisLeishmania donovani depletes labile iron pool to exploit iron uptake capacity of macrophage for its intracellular growth.Attenuated Leishmania induce pro-inflammatory mediators and influence leishmanicidal activity by p38 MAPK dependent phagosome maturation in Leishmania donovani co-infected macrophages.Molecular identification of an old clinical isolate of Indian Kala-azar.Hybrid cell vaccination resolves Leishmania donovani infection by eliciting a strong CD8+ cytotoxic T-lymphocyte response with concomitant suppression of interleukin-10 (IL-10) but not IL-4 or IL-13.Vaccination route that induces transforming growth factor beta production fails to elicit protective immunity against Leishmania donovani infection.Liposomal Elongation Factor-1α Triggers Effector CD4 and CD8 T Cells for Induction of Long-Lasting Protective Immunity against Visceral Leishmaniasis.
P2860
Q33392744-4B1A87CC-3753-4E1E-9194-5FCB929B1FA1Q33463435-8D8550D3-96D7-43B2-BF7A-D8F6BC352C7CQ35433080-BC76965B-379F-409B-932A-7A69362B8B91Q36095926-C1BE957A-0180-4A7B-BD8F-2CD24C26BFD2Q37053213-7CCB78E9-50D9-4F68-BF69-139CFDD99B2DQ37414550-6DF82674-3F72-4E87-B8EB-9E0D674654F8Q38688691-242179F6-5C7A-4555-9610-FBACBEA226F8Q39211481-F3460117-F10B-485A-98C0-9375ABA4B072Q40073796-3C72206A-061E-4F32-BD83-5B4A6D2E06EBQ41870296-9B5046AE-F309-4B8F-BECE-9E3DAC27916DQ49210114-E51A1824-34BD-44F0-B571-A0B8CBDA7528
P2860
Use of an attenuated leishmanial parasite as an immunoprophylactic and immunotherapeutic agent against murine visceral leishmaniasis
description
2000 nî lūn-bûn
@nan
2000 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մարտին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Use of an attenuated leishmani ...... murine visceral leishmaniasis
@ast
Use of an attenuated leishmani ...... murine visceral leishmaniasis
@en
type
label
Use of an attenuated leishmani ...... murine visceral leishmaniasis
@ast
Use of an attenuated leishmani ...... murine visceral leishmaniasis
@en
prefLabel
Use of an attenuated leishmani ...... murine visceral leishmaniasis
@ast
Use of an attenuated leishmani ...... murine visceral leishmaniasis
@en
P2093
P2860
P1476
Use of an attenuated leishmani ...... murine visceral leishmaniasis
@en
P2093
S Bhattacharyya
S Majumdar
S Mukhopadhyay
P2860
P304
P356
10.1128/CDLI.7.2.233-240.2000
P577
2000-03-01T00:00:00Z